Management of secondary hyperparathyroidism of dialysis patients

Tadao Akizawa, Motohiro Kamimura, Masahide Mizobuchi, Kazuhiro Shiizaki, Shinji Sumikado, Toshibumi Sakaguchi, Shigeo Negi, Hiroaki Ogata, Eriko Kinugasa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hyperphosphatemia, vitamin D deficiency, and resulted hypocalcemia have been regarded as classical pathogeneses of secondary hyperparathyroidism. These factors have been treated by the administration of phosphorus binder and vitamin D derivatives. However, these therapies have not brought about a successful result for the prevention and treatment of secondary hyperparathyroidism. The reason could be mainly attributed to the hypercalcemia that results from the administration of calcium salts as a phosphorus binder and the calcemic action of vitamin D. To prevent hypercalcemia, non-calcium containing phosphorus binder (sevelamer hydrochloride) and vitamin D analogues, which suppress PTH secretion with minimum calcemic action, have been developed. These new vitamin D analogues include 19-nor-1-alpha, 25-dihydroxyvitamin D2 (paricalcitol), 1-alpha-hydroxyvitamin D2 (doxercalciferol), 22oxa-calcitriol (maxacalcitol) and F6-calcitriol (falecalcitriol). Furthermore, calcimimetics that stimulate calcium-sensing receptor of parathyroid cells as calcium and suppress PTH secretion are now under clinical trial. Percutaneous direct injection therapy of vitamin D, vitamin D analogue or calcimimetics into parathyroid gland has also been reported. The combination of these new strategies is expected to effectively and safely suppresses secondary hyperparathyroidism that has been resistant to conventional medical treatments.

Original languageEnglish (US)
JournalNephrology
Volume8
Issue numberSUPPL.
DOIs
StatePublished - Oct 2003

Fingerprint

Secondary Hyperparathyroidism
Vitamin D
Dialysis
Phosphorus
Calcitriol
Hypercalcemia
Calcium
Hyperphosphatemia
Calcium-Sensing Receptors
Parathyroid Glands
Vitamin D Deficiency
Hypocalcemia
Therapeutics
Salts
Clinical Trials
Injections

Keywords

  • Calcimimetics
  • Maxacalcitol
  • Percutaneous intervention therapy
  • Phosphorus binder
  • Secondary hyperparathyroidism
  • Vitamin D

ASJC Scopus subject areas

  • Nephrology

Cite this

Akizawa, T., Kamimura, M., Mizobuchi, M., Shiizaki, K., Sumikado, S., Sakaguchi, T., ... Kinugasa, E. (2003). Management of secondary hyperparathyroidism of dialysis patients. Nephrology, 8(SUPPL.). https://doi.org/10.1046/j.1440-1797.8.s.9.x

Management of secondary hyperparathyroidism of dialysis patients. / Akizawa, Tadao; Kamimura, Motohiro; Mizobuchi, Masahide; Shiizaki, Kazuhiro; Sumikado, Shinji; Sakaguchi, Toshibumi; Negi, Shigeo; Ogata, Hiroaki; Kinugasa, Eriko.

In: Nephrology, Vol. 8, No. SUPPL., 10.2003.

Research output: Contribution to journalArticle

Akizawa, T, Kamimura, M, Mizobuchi, M, Shiizaki, K, Sumikado, S, Sakaguchi, T, Negi, S, Ogata, H & Kinugasa, E 2003, 'Management of secondary hyperparathyroidism of dialysis patients', Nephrology, vol. 8, no. SUPPL.. https://doi.org/10.1046/j.1440-1797.8.s.9.x
Akizawa T, Kamimura M, Mizobuchi M, Shiizaki K, Sumikado S, Sakaguchi T et al. Management of secondary hyperparathyroidism of dialysis patients. Nephrology. 2003 Oct;8(SUPPL.). https://doi.org/10.1046/j.1440-1797.8.s.9.x
Akizawa, Tadao ; Kamimura, Motohiro ; Mizobuchi, Masahide ; Shiizaki, Kazuhiro ; Sumikado, Shinji ; Sakaguchi, Toshibumi ; Negi, Shigeo ; Ogata, Hiroaki ; Kinugasa, Eriko. / Management of secondary hyperparathyroidism of dialysis patients. In: Nephrology. 2003 ; Vol. 8, No. SUPPL.
@article{e825b51ecf2b4602bc374645653f5094,
title = "Management of secondary hyperparathyroidism of dialysis patients",
abstract = "Hyperphosphatemia, vitamin D deficiency, and resulted hypocalcemia have been regarded as classical pathogeneses of secondary hyperparathyroidism. These factors have been treated by the administration of phosphorus binder and vitamin D derivatives. However, these therapies have not brought about a successful result for the prevention and treatment of secondary hyperparathyroidism. The reason could be mainly attributed to the hypercalcemia that results from the administration of calcium salts as a phosphorus binder and the calcemic action of vitamin D. To prevent hypercalcemia, non-calcium containing phosphorus binder (sevelamer hydrochloride) and vitamin D analogues, which suppress PTH secretion with minimum calcemic action, have been developed. These new vitamin D analogues include 19-nor-1-alpha, 25-dihydroxyvitamin D2 (paricalcitol), 1-alpha-hydroxyvitamin D2 (doxercalciferol), 22oxa-calcitriol (maxacalcitol) and F6-calcitriol (falecalcitriol). Furthermore, calcimimetics that stimulate calcium-sensing receptor of parathyroid cells as calcium and suppress PTH secretion are now under clinical trial. Percutaneous direct injection therapy of vitamin D, vitamin D analogue or calcimimetics into parathyroid gland has also been reported. The combination of these new strategies is expected to effectively and safely suppresses secondary hyperparathyroidism that has been resistant to conventional medical treatments.",
keywords = "Calcimimetics, Maxacalcitol, Percutaneous intervention therapy, Phosphorus binder, Secondary hyperparathyroidism, Vitamin D",
author = "Tadao Akizawa and Motohiro Kamimura and Masahide Mizobuchi and Kazuhiro Shiizaki and Shinji Sumikado and Toshibumi Sakaguchi and Shigeo Negi and Hiroaki Ogata and Eriko Kinugasa",
year = "2003",
month = "10",
doi = "10.1046/j.1440-1797.8.s.9.x",
language = "English (US)",
volume = "8",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "SUPPL.",

}

TY - JOUR

T1 - Management of secondary hyperparathyroidism of dialysis patients

AU - Akizawa, Tadao

AU - Kamimura, Motohiro

AU - Mizobuchi, Masahide

AU - Shiizaki, Kazuhiro

AU - Sumikado, Shinji

AU - Sakaguchi, Toshibumi

AU - Negi, Shigeo

AU - Ogata, Hiroaki

AU - Kinugasa, Eriko

PY - 2003/10

Y1 - 2003/10

N2 - Hyperphosphatemia, vitamin D deficiency, and resulted hypocalcemia have been regarded as classical pathogeneses of secondary hyperparathyroidism. These factors have been treated by the administration of phosphorus binder and vitamin D derivatives. However, these therapies have not brought about a successful result for the prevention and treatment of secondary hyperparathyroidism. The reason could be mainly attributed to the hypercalcemia that results from the administration of calcium salts as a phosphorus binder and the calcemic action of vitamin D. To prevent hypercalcemia, non-calcium containing phosphorus binder (sevelamer hydrochloride) and vitamin D analogues, which suppress PTH secretion with minimum calcemic action, have been developed. These new vitamin D analogues include 19-nor-1-alpha, 25-dihydroxyvitamin D2 (paricalcitol), 1-alpha-hydroxyvitamin D2 (doxercalciferol), 22oxa-calcitriol (maxacalcitol) and F6-calcitriol (falecalcitriol). Furthermore, calcimimetics that stimulate calcium-sensing receptor of parathyroid cells as calcium and suppress PTH secretion are now under clinical trial. Percutaneous direct injection therapy of vitamin D, vitamin D analogue or calcimimetics into parathyroid gland has also been reported. The combination of these new strategies is expected to effectively and safely suppresses secondary hyperparathyroidism that has been resistant to conventional medical treatments.

AB - Hyperphosphatemia, vitamin D deficiency, and resulted hypocalcemia have been regarded as classical pathogeneses of secondary hyperparathyroidism. These factors have been treated by the administration of phosphorus binder and vitamin D derivatives. However, these therapies have not brought about a successful result for the prevention and treatment of secondary hyperparathyroidism. The reason could be mainly attributed to the hypercalcemia that results from the administration of calcium salts as a phosphorus binder and the calcemic action of vitamin D. To prevent hypercalcemia, non-calcium containing phosphorus binder (sevelamer hydrochloride) and vitamin D analogues, which suppress PTH secretion with minimum calcemic action, have been developed. These new vitamin D analogues include 19-nor-1-alpha, 25-dihydroxyvitamin D2 (paricalcitol), 1-alpha-hydroxyvitamin D2 (doxercalciferol), 22oxa-calcitriol (maxacalcitol) and F6-calcitriol (falecalcitriol). Furthermore, calcimimetics that stimulate calcium-sensing receptor of parathyroid cells as calcium and suppress PTH secretion are now under clinical trial. Percutaneous direct injection therapy of vitamin D, vitamin D analogue or calcimimetics into parathyroid gland has also been reported. The combination of these new strategies is expected to effectively and safely suppresses secondary hyperparathyroidism that has been resistant to conventional medical treatments.

KW - Calcimimetics

KW - Maxacalcitol

KW - Percutaneous intervention therapy

KW - Phosphorus binder

KW - Secondary hyperparathyroidism

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=0348224186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348224186&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1797.8.s.9.x

DO - 10.1046/j.1440-1797.8.s.9.x

M3 - Article

VL - 8

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - SUPPL.

ER -